Deutsch English Français

Contact

EP2300055

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2300055

EP2300055 - ANTICANCER COMBINATION THERAPY INCLUDING TRICIRIBINE [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 06.04.2018 Database last updated on 18.01.2025
Former	Examination is in progress Status updated on 25.11.2016
Most recent event Tooltip	06.04.2018	Application deemed to be withdrawn	published on 09.05.2018 [2018/19]
Applicant(s)	For all designated states University Of South Florida 3702 Spectrum Blvd., Suite 155 Tampa, FL 33612-9445 / US
	[2011/13]
Inventor(s)	01 / CHENG, Jin Q. 9613 Fox Hearst Road Tampa Florida 33647 / US
	02 / SEBTI, Said M. 8957 Magnolia Chase Circle Tampa Florida 33647 / US
	[2011/13]
Representative(s)	Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
	[N/P]
Former [2012/24]	Kilger, Christian, et al Fanelli Haag & Kilger PLLC Fasanenstraße 29 10719 Berlin / DE
Former [2011/13]	Kilger, Christian, et al Vossius & Partner Siebertstrasse 4 81675 München / DE
Application number, filing date	08755326.9	12.05.2008
	[2011/13]
	WO2008US63449
Priority number, date	US20080118848	12.05.2008 Original published format: US 118848
	US20080118861	12.05.2008 Original published format: US 118861
	US20080118868	12.05.2008 Original published format: US 118868
	US20080118870	12.05.2008 Original published format: US 118870
	US20080118828	12.05.2008 Original published format: US 118828
	US20080118834	12.05.2008 Original published format: US 118834
	[2011/13]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2009139766
	Date:	19.11.2009
	Language:	EN
	[2009/47]
	Type:	A1 Application with search report
	No.:	EP2300055
	Date:	30.03.2011
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 19.11.2009 takes the place of the publication of the European patent application.
	[2011/13]
Search report(s)	International search report - published on:	EP	19.11.2009
Classification	IPC:	A61K45/06, A61P35/00, A61K31/7076, A61K39/395, A61K31/4353, A61K31/337, A61K31/282, A61K33/24	[2011/13]
	CPC:	A61K31/7064 (EP,US); A61K31/282 (EP,US); A61K31/337 (EP,US); A61K31/4353 (EP,US); A61K31/7076 (EP,US); A61K33/24 (EP,US); (+) A61K33/243 (EP,US); A61K33/244 (EP,US); A61K39/39558 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP); A61P43/00 (EP); C07K16/2863 (US); A61K2039/505 (US); A61K51/00 (EP,US); C07K2317/24 (US); C07K2317/76 (US) (-)
	C-Set:	A61K31/282, A61K2300/00 (EP,US); A61K31/337, A61K2300/00 (US,EP); A61K31/4353, A61K2300/00 (US,EP); A61K31/7076, A61K2300/00 (US,EP); (+) A61K33/24, A61K2300/00 (EP,US); A61K39/39558, A61K2300/00 (EP,US) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2011/13]
Title	German:	TRICIRIBIN UMFASSENDE KOMBINATIONSTHERAPIE GEGEN KREBS	[2011/13]
	English:	ANTICANCER COMBINATION THERAPY INCLUDING TRICIRIBINE	[2011/13]
	French:	THÉRAPIE DE COMBINAISON ANTICANCÉREUSE COMPRENANT DE LA TRICIRIBINE	[2011/13]
Entry into regional phase	10.12.2010	National basic fee paid
	10.12.2010	Designation fee(s) paid
	10.12.2010	Examination fee paid
Examination procedure	10.12.2010	Amendment by applicant (claims and/or description)
	10.12.2010	Examination requested [2011/13]
	19.02.2016	Despatch of a communication from the examining division (Time limit: M04)
	23.06.2016	Reply to a communication from the examining division
	16.11.2016	Despatch of a communication from the examining division (Time limit: M04)
	27.03.2017	Reply to a communication from the examining division
	01.12.2017	Application deemed to be withdrawn, date of legal effect [2018/19]
	04.01.2018	Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2018/19]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 19.02.2016
Fees paid	Renewal fee
	17.12.2010	Renewal fee patent year 03
	31.05.2011	Renewal fee patent year 04
	15.05.2012	Renewal fee patent year 05
	13.11.2013	Renewal fee patent year 06
	21.05.2014	Renewal fee patent year 07
	27.05.2015	Renewal fee patent year 08
	20.05.2016	Renewal fee patent year 09
	Penalty fee
	Additional fee for renewal fee
	12.12.2010	03 M06 Fee paid on 17.12.2010
	31.05.2013	06 M06 Fee paid on 13.11.2013
	31.05.2017	10 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[XI]WO2005094322 (UNIV SOUTH FLORIDA [US], et al) [X] 1,6-8,15,20-24 * pages 77-78; claim - * * page 74, lines 2-12; claim - * [I] 2-5,9-14,16-19,25-27;
		[E]WO2008060581 (CLEVELAND CLINIC FOUNDATION [US], et al) [E] 1-27 * pages 7-18; example -; claim - *;
		[E]WO2008070100 (UNIV SOUTH FLORIDA [US], et al) [E] 1-27 * figure 9; claim - *;
		[E]WO2008094321 (UNIVERSTIY OF SOUTH FLORIDA [US], et al) [E] 1-27 * claims 1-3 *;
		[XI] - LU CHIEN-HSING ET AL, "Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20071001), vol. 13, no. 19, ISSN 1078-0432, pages 5883 - 5888, XP002472826 [X] 1,2,15,23 * pages 5887-8; figure - * [I] 3-14,16-22,24-27 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-06-2837
		[XI] - YU DIHUA ET AL, "Strategies for overcoming trastuzumab resistance caused by PTEN deficiency", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, & 99TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; SAN DIEGO, CA, USA; APRIL 12 -16, 2008, (200804), vol. 49, ISSN 0197-016X, page 159, XP001537112 [X] 1,2,15,23 * the whole document * [I] 3-14,16-22,24-27
		[I] - KENG-HSUEH LAN ET AL, "Mechanisms of Trastuzumab Resistance and their Clinical Implications", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, (20050101), vol. 1059, ISSN 0077-8923, pages 70 - 75, XP009097340 [I] 1-27 * page 73 * DOI: http://dx.doi.org/10.1196/annals.1339.026
		[A] - CHENG J Q ET AL, "The Akt/PKB pathway: Molecular target for cancer drug discovery", ONCOGENE 20051114 GB, (20051114), vol. 24, no. 50, ISSN 0950-9232 1476-5594, pages 7482 - 7492, XP008104381 [A] 1-27 * page 7488 * * page 7490, column R * DOI: http://dx.doi.org/10.1038/SJ.ONC.1209088

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p